Variant of TREM2 Associated with the Risk of Alzheimer's Disease
2012/11/14 by Thorlákur Jónsson, Thorlakur Jonsson, Hreinn Stefansson +31 · 2,635 citations
Immunology and Microbiology · Medicine · Neuroscience · #Allele #Alzheimer's disease #Apolipoprotein E #Biology #Case-control study #Confidence interval #Disease #Gene #Genetics #Inflammation biomarkers and pathways #Internal medicine #Medicine #Missense mutation #Mutation #Neuroinflammation and Neurodegeneration Mechanisms #Neurological Disease Mechanisms and Treatments #Odds ratio #Population #Receptor #TREM2
paper · open access · doi:10.1056/nejmoa1211103
published in New England Journal of Medicine 368(2), 107-116 (Massachusetts Medical Society)
openalex publication_date 2012/11/14 · openalex created_date 2016/06/24 · openalex updated_date 2026/08/02
Abstract
BACKGROUND: Sequence variants, including the ε4 allele of apolipoprotein E, have been associated with the risk of the common late-onset form of Alzheimer's disease. Few rare variants affecting the risk of late-onset Alzheimer's disease have been found. METHODS: We obtained the genome sequences of 2261 Icelanders and identified sequence variants that were likely to affect protein function. We imputed these variants into the genomes of patients with Alzheimer's disease and control participants and then tested for an association with Alzheimer's disease. We performed replication tests using case-control series from the United States, Norway, The Netherlands, and Germany. We also tested for a genetic association with cognitive function in a population of unaffected elderly persons. RESULTS: A rare missense mutation (rs75932628-T) in the gene encoding the triggering receptor expressed on myeloid cells 2 (TREM2), which was predicted to result in an R47H substitution, was found to confer a significant risk of Alzheimer's disease in Iceland (odds ratio, 2.92; 95% confidence interval [CI], 2.09 to 4.09; P=3.42×10(-10)). The mutation had a frequency of 0.46% in controls 85 years of age or older. We observed the association in additional sample sets (odds ratio, 2.90; 95% CI, 2.16 to 3.91; P=2.1×10(-12) in combined discovery and replication samples). We also found that carriers of rs75932628-T between the ages of 80 and 100 years without Alzheimer's disease had poorer cognitive function than noncarriers (P=0.003). CONCLUSIONS: Our findings strongly implicate variant TREM2 in the pathogenesis of Alzheimer's disease. Given the reported antiinflammatory role of TREM2 in the brain, the R47H substitution may lead to an increased predisposition to Alzheimer's disease through impaired containment of inflammatory processes. (Funded by the National Institute on Aging and others.).
Citations
Cited by
- A multi-looping chromatin signature predicts dysregulated gene expression in neurons with familial Alzheimer’s disease mutations
- Blood-Brain Barrier: From Physiology to Disease and Back
- Alzheimer's disease‐associated R47H TREM2 increases, but wild‐type TREM2 decreases, microglial phagocytosis of synaptosomes and neuronal loss
- NLRP3 Inflammasome Inhibitor Ameliorates Amyloid Pathology in a Mouse Model of Alzheimer’s Disease
- Moving beyond amyloid and tau to capture the biological heterogeneity of Alzheimer’s disease
- Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia
- Immune signaling and function in neurodegeneration
- Microglia‐synapse engulfment via PtdSer‐TREM2 ameliorates neuronal hyperactivity in Alzheimer's disease models
- ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease
- Analysis of whole genome sequence data shows association of Alzheimer’s disease with rare coding variants in ABCA7 , PSEN1 , SORL1 and TREM2
- The connection between autophagy and Alzheimer’s disease
- Biophysical mapping of TREM2-ligand interactions reveals shared surfaces for engagement of multiple Alzheimer’s disease ligands
- Triggering receptor expressed on myeloid cells-2 expression in the brain is required for maximal phagocytic activity and improved neurological outcomes following experimental stroke
- TREM2 is required for microglial instruction of astrocytic synaptic engulfment in neurodevelopment
- Microglia directly associate with pericytes in the central nervous system
- Lipid transporter Spns2 promotes microglia pro‐inflammatory activation in response to amyloid‐beta peptide
- iPSC‐derived microglia carrying the TREM2 R47H/+ mutation are proinflammatory and promote synapse loss
- Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
- Bioenergetics and lipid metabolism in Alzheimer's disease: From cell biology to systemic health
- Recent Advances Towards Diagnosis and Therapeutic Fingerprinting for Alzheimer’s Disease
- NEBULA is a fast negative binomial mixed model for differential or co-expression analysis of large-scale multi-subject single-cell data
- Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
- Microglia and amyloid plaque formation in Alzheimer's disease – Evidence, possible mechanisms, and future challenges
- Analysis of Cerebrospinal Fluid Soluble TREM2 and Polymorphisms in Sporadic Parkinson’s Disease in a Chinese Population
- Large-scale integration of the plasma proteome with genetics and disease
- Ethanol induces neuroimmune dysregulation and soluble TREM2 generation in a human iPSC neuron, astrocyte, microglia triculture model
- A microglia clonal inflammatory disorder in Alzheimer’s disease
- TREM2 in Alzheimer's disease: Structure, function, therapeutic prospects, and activation challenges
- Bio-ecología del picudo rojo de las palmeras, Rhynchophorus ferrugineus (Coleoptera: Curculionidae)
- Microglial genes regulating neuroinflammation in the progression of Alzheimer's disease
- Heterozygous TREM2 mutations in frontotemporal dementia
- Microglia Function in the Central Nervous System During Health and Neurodegeneration
- TREM2 R47H variant and risk for Alzheimer’s disease: assessment in a Greek population and updated meta-analysis
- Alzheimer's disease
- Alzheimer’s Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid
- Genome-wide Association Studies in Alzheimer’s Disease: A Review
- Concussion, microvascular injury, and early tauopathy in young athletes after impact head injury and an impact concussion mouse model
- Genetics of Chronic Traumatic Encephalopathy
- esyN: Network Building, Sharing and Publishing
- Trem2 promotes anti-inflammatory responses in microglia and is suppressed under pro-inflammatory conditions
- Alzheimer’s disease basics: we all should know
- Amyloid-β induces lipid droplet-mediated microglial dysfunction via the enzyme DGAT2 in Alzheimer’s disease
- Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. [europepmc]
- Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. [europepmc]
- The microglial sensome revealed by direct RNA sequencing. [europepmc]
- Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. [europepmc]
- Biomarker modeling of Alzheimer's disease. [europepmc]
- Alzheimer's disease risk genes and mechanisms of disease pathogenesis. [europepmc]
- TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. [europepmc]
- Ageing, neurodegeneration and brain rejuvenation. [europepmc]
- Microglia Function in the Central Nervous System During Health and Neurodegeneration. [europepmc]
- Amyloid beta: structure, biology and structure-based therapeutic development. [europepmc]
- Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. [europepmc]
- Microglia in Alzheimer's disease. [europepmc]
- Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines. [europepmc]
- Microglial signatures and their role in health and disease. [europepmc]
- Microglia in neurodegeneration. [europepmc]
- Blood-Brain Barrier: From Physiology to Disease and Back. [europepmc]
- Inflammation as a central mechanism in Alzheimer's disease. [europepmc]
- Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. [europepmc]
- Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. [europepmc]
- Lipid-Associated Macrophages Control Metabolic Homeostasis in a Trem2-Dependent Manner. [europepmc]
- Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. [europepmc]
- Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. [europepmc]
- Alzheimer's disease. [europepmc]
- Inflammation in obesity, diabetes, and related disorders. [europepmc]
- Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets. [europepmc]
Related